Needham analyst David Saxon reiterated a Buy rating on CryoPort today and set a price target of $13.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
David Saxon has given his Buy rating due to a combination of factors, primarily CryoPort’s stronger‑than‑expected fourth‑quarter 2025 revenue, which was fueled by robust performance in its Life Sciences Services segment. In addition, management’s 2026 revenue outlook came in above the Street’s expectations at the midpoint, signaling confidence in the company’s growth trajectory.
He also highlights that CryoPort anticipates turning adjusted EBITDA positive in the second half of 2026 as operating expenses become more efficient, indicating improving profitability. In light of this operational momentum and the favorable forward guidance, Saxon not only reiterates his Buy recommendation but also increases his price target to $13, reflecting a more optimistic valuation framework.
In another report released yesterday, Roth MKM also maintained a Buy rating on the stock with a $15.00 price target.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CYRX in relation to earlier this year.